American College Of Surgeons - Inspiring Quality: Highest Standards, Better Outcomes

Best Practices in the Diagnosis and Treatment of Inflammatory Breast Cancer Webinar

Presented by Beth Overmoyer, MD, FACP
Thursday, September 12, 2019
11:00–12:00 pm (CDT)

Inflammatory breast cancer signs and symptoms mimic mastitis. Many physicians do not recognize that mastitis is common in younger, premenopausal women but uncommon in the post-menopausal population. The rarity of inflammatory breast cancer compared with the frequency of mastitis or cellulitis of the breast often results in a delay of a cancer work-up in favor of treating mastitis. This delay may affect the patient’s clinical course thus increasing the possibility of symptomatic spread of breast cancer and associated outcomes.

The webinar will review the clinical presentation of inflammatory breast cancer, discuss the NCCN guidelines for inflammatory breast cancer, and best practices for early diagnosis by primary care physicians, ob-gyn specialists, and advance practice providers.

Learning Objectives

  • Describe the common presentation of inflammatory breast cancer and the characteristics that differentiate it from locally advanced disease.
  • Identify best practice options for the timely diagnosis of inflammatory breast cancer.
  • Discuss the NCCN guidelines for inflammatory breast cancer and compare the differences to the guidelines for non-inflammatory invasive breast cancer.

Target Audience

  • Primary care providers
  • Ob-Gyn specialists
  • Advance practice providers
  • NAPBC centers staff
  • Patient advocacy organizations

More about Beth Overmoyer

Beth Overmoyer, MD, FACP, is a national and international expert on inflammatory breast cancer. She is currently the director of the Inflammatory Breast Cancer Program at Dana-Farber Cancer Institute, which is one of three dedicated programs in the United States focusing on the care of patients with inflammatory breast cancer. Dr. Overmoyer received her MD from Case Western Reserve School of Medicine followed by training in internal medicine and hematology and oncology at the Hospital of the University of Pennsylvania. She became the director of breast cancer research under the Case Comprehensive Cancer Center in Cleveland prior to joining Dana Farber. In addition to publishing extensively on inflammatory breast cancer, Dr. Overmoyer has been the principal investigator of several clinical trials designed specifically for inflammatory breast cancer and oversees the translational research that result from these studies.

Registration will open in mid-Summer.